Prostate cancer detection in men with a 'normal' total prostate-specific antigen (PSA) level using percentage free PSA: A prospective screening study

BJU International

Volumn 95, Issue 9, 2005, Pages 1249-1252

  Rowe, Edward W J ^a   Laniado, Mark E ^b   Walker, Marjorie M ^a   Patel, Anup ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

^b WEXHAM PARK HOSPITAL   (United Kingdom)

Author keywords

Detection; Normal total PSA; Percentage free PSA; Prostate cancer; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CANCER SCREENING; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; TUMOR VOLUME;

AGED; BIOPSY; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC;

EID: 20444409181     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2005.05514.x     Document Type: Article

References (13)

1. Thompson IM, Pauler DK, Goodman PJ et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 2004; 350: 2239-46
2. Schroder FH, de Koning HJ, Vis AN, Hoedemaeker RF, Kranse R. Prostate cancer detection at low prostate specific antigen. J Urol 2000; 163: 806-12
3. Partin AW, Kattan MW, Subong EN et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997; 277: 1445-51
4. Carter HB, Epstein JI, Chan DW, Fozard JL, Pearson JD. Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer. JAMA 1997; 277: 1456-60
5. Catalona WJ, Partin AW, Slawin KM et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998; 279: 1542-7
6. Catalona WJ, Partin AW, Finlay JA et al. Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51-4 ng/mL and digital rectal examination is not suspicious for prostate cancer: an alternative model. Urology 1999; 54: 220-4
7. Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55-74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998; 280: 975-80
8. Stanford JL, Feng Z, Hamilton AS et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA 2000; 283: 354-60
9. Recker F, Kwiatkowski MK, Huber A, Stamm B, Lehmann K, Tscholl R. Prospective detection of clinically relevant prostate cancer in the prostate specific antigen range 1-3 ng./ml. combined with free-to-total ratio 20% or less: the Aarau experience. J Urol 2001; 166: 851-5
10. Miettinen OS, Henschke CI, Pasmantier MW, Smith JP, Libby DM, Yankelevitz DF. Mammographic screening: no reliable supporting evidence? Lancet 2002; 359: 404-5
11. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6-4.0 ng/ mLand benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 1997; 277: 1452-5
12. Chan LW, Stamey TA. Calculating prostate cancer volume preoperatively. The D'Amico equation and some other observations. J Urol 1998; 159: 1998-2003
13. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage Tic) prostate cancer. JAMA 1994; 271: 368-74